Akebia Therapeutics Q1 2024 Earnings Report $1.88 +0.01 (+0.27%) (As of 01:15 PM ET) Earnings HistoryForecast Akebia Therapeutics EPS ResultsActual EPS-$0.09Consensus EPS -$0.09Beat/MissMet ExpectationsOne Year Ago EPS-$0.14Akebia Therapeutics Revenue ResultsActual Revenue$32.61 millionExpected Revenue$41.13 millionBeat/MissMissed by -$8.52 millionYoY Revenue GrowthN/AAkebia Therapeutics Announcement DetailsQuarterQ1 2024Date5/9/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseAKBA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Akebia Therapeutics Earnings HeadlinesAkebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18 at 8:00 AM | prnewswire.comAkebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trialDecember 3, 2024 | markets.businessinsider.comHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 18, 2024 | Porter & Company (Ad)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | prnewswire.comU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on DialysisDecember 3, 2024 | prnewswire.comAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceNovember 25, 2024 | prnewswire.comSee More Akebia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akebia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akebia Therapeutics and other key companies, straight to your email. Email Address About Akebia TherapeuticsAkebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.View Akebia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
